PTJ
ALT icon

Paul Tudor Jones’s Altimmune ALT Stock Holding History

Paul Tudor Jones’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-22,501
Closed -$79.4K – 2248
2023
Q2 		$79.4K Buy
+22,501
New +$101K ﹤0.01% 2308
2022
Q4 		– Sell
-18,607
Closed -$238K – 2331
2022
Q3 		$238K Buy
+18,607
New +$275K 0.01% 1947

Other funds holding ALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Paul Tudor Jones's ALT Position: Q3 2023 in Review

Paul Tudor Jones sold out of Altimmune (ALT) in Q3 2023, closing a stake of 22,501 shares — an estimated $79.4K sold.

Paul Tudor Jones first reported a position in ALT in Q3 2022 and held it in 2 quarters. The position peaked at $238K in Q3 2022. 112 funds tracked by Wall St. Rank hold ALT as of Q3 2023.

  • Paul Tudor Jones reported no remaining Altimmune position as of Q3 2023 after selling out during the quarter.
  • Paul Tudor Jones sold 22,501 Altimmune shares in Q3 2023, an estimated $79.4K.
  • Paul Tudor Jones first reported a position in Altimmune in Q3 2022 and held it in 2 quarters.
  • Paul Tudor Jones's Altimmune position peaked at $238K in Q3 2022.
  • 112 funds tracked by Wall St. Rank held Altimmune as of Q3 2023.

Based on Tudor Investment Corp's 13F filing for Q3 2023, filed 15 Nov 2023.